|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q56427374
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241221010721.0 |
|
008
|
|
|
241221nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q56427374
|
|
024
|
|
|
‡a
0000-0003-1579-8513
‡2
orcid
|
|
024
|
|
|
‡a
35726117600
‡2
scopus
|
|
035
|
|
|
‡a
(OCoLC)Q56427374
|
|
100
|
0 |
|
‡a
Marta O Soares
‡c
researcher
‡9
en-gb
|
|
375
|
|
|
‡a
2
‡2
iso5218
|
|
400
|
0 |
|
‡a
Marta O Soares
‡c
researcher
‡9
en
|
|
400
|
0 |
|
‡a
Marta O Soares
‡c
wetenschapper
‡9
nl
|
|
670
|
|
|
‡a
Author's A pilot randomised controlled trial of negative pressure wound therapy to treat grade III/IV pressure ulcers [ISRCTN69032034].
|
|
670
|
|
|
‡a
Author's A pragmatic multi-centred randomised controlled trial of yoga for chronic low back pain: trial protocol
|
|
670
|
|
|
‡a
Author's A pragmatic multicentered randomized controlled trial of yoga for chronic low back pain: economic evaluation
|
|
670
|
|
|
‡a
Author's Accounting for Heterogeneity in Relative Treatment Effects for Use in Cost-Effectiveness Models and Value-of-Information Analyses.
|
|
670
|
|
|
‡a
Author's Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial
|
|
670
|
|
|
‡a
Author's Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT
|
|
670
|
|
|
‡a
Author's An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value [...]
|
|
670
|
|
|
‡a
Author's An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of inf
|
|
670
|
|
|
‡a
Author's Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer
|
|
670
|
|
|
‡a
Author's Capecitabine for the treatment of advanced gastric cancer.
|
|
670
|
|
|
‡a
Author's Clinical and cost-effectiveness of compression hosiery versus compression bandages in treatment of venous leg ulcers (Venous leg Ulcer Study IV, VenUS IV): a randomised controlled trial
|
|
670
|
|
|
‡a
Author's Cost effectiveness analysis of larval therapy for leg ulcers.
|
|
670
|
|
|
‡a
Author's Critical appraisal of cost-effectiveness and cost-utility studies in health care
|
|
670
|
|
|
‡a
Author's Economic evaluation of healthcare technologies using primary research
|
|
670
|
|
|
‡a
Author's Health Opportunity Costs: Assessing the Implications of Uncertainty Using Elicitation Methods with Experts
|
|
670
|
|
|
‡a
Author's Hospital Resource Utilization and Treatment Cost of Skeletal-Related Events in Patients with Metastatic Breast or Prostate Cancer: Estimation for the Portuguese National Health System
|
|
670
|
|
|
‡a
Author's Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial
|
|
670
|
|
|
‡a
Author's Is the QALY blind, deaf and dumb to equity? NICE's considerations over equity.
|
|
670
|
|
|
‡a
Author's Larval therapy for leg ulcers
|
|
670
|
|
|
‡a
Author's Larval therapy for leg ulcers (VenUS II): randomised controlled trial.
|
|
670
|
|
|
‡a
Author's Making best use of evidence for explicit decisions in health care
|
|
670
|
|
|
‡a
Author's Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold
|
|
670
|
|
|
‡a
Author's Methods to assess cost-effectiveness and value of further research when data are sparse: negative-pressure wound therapy for severe pressure ulcers
|
|
670
|
|
|
‡a
Author's Methods to elicit experts' beliefs over uncertain quantities: application to a cost effectiveness transition model of negative pressure wound therapy for severe pressure ulceration
|
|
670
|
|
|
‡a
Author's Modelos de decisão para avaliações econômicas de tecnologias em saúde
|
|
670
|
|
|
‡a
Author's Network meta-analysis of (individual patient) time to event data alongside (aggregate) count data
|
|
670
|
|
|
‡a
Author's Point-of-care creatinine tests to assess kidney function for outpatients requiring contrast-enhanced CT imaging: systematic reviews and economic evaluation
|
|
670
|
|
|
‡a
Author's Systematic review and mixed treatment comparison: dressings to heal diabetic foot ulcers.
|
|
670
|
|
|
‡a
Author's The added clinical and economic value of diagnostic testing for epilepsy surgery.
|
|
670
|
|
|
‡a
Author's The clinical effectiveness and cost-effectiveness of technologies used to visualise the seizure focus in people with refractory epilepsy being considered for surgery: a systematic review and decision-analytical model.
|
|
670
|
|
|
‡a
Author's Use of weekly, low dose, high frequency ultrasound for hard to heal venous leg ulcers: the VenUS III randomised controlled trial.
|
|
670
|
|
|
‡a
Author's VenUS II: a randomised controlled trial of larval therapy in the management of leg ulcers.
|
|
670
|
|
|
‡a
Author's VenUS IV (Venous leg Ulcer Study IV) - compression hosiery compared with compression bandaging in the treatment of venous leg ulcers: a randomised controlled trial, mixed-treatment comparison and decision-analytic model
|
|
670
|
|
|
‡a
wikidata authority control
‡u
https://viaf.org/viaf/121921967
|
|
670
|
|
|
‡a
wikidata authority control
‡u
https://viaf.org/processed/LC|n 2010182193
|
|
909
|
|
|
‡a
(scopus) 35726117600
‡9
1
|
|
909
|
|
|
‡a
(orcid) 0000000315798513
‡9
1
|
|
919
|
|
|
‡a
istheqalyblinddeafanddumbtoequitynicesconsiderationsoverequity
‡A
Is the QALY blind, deaf and dumb to equity? NICE's considerations over equity.
‡9
1
|
|
919
|
|
|
‡a
hospitalresourceutilizationandtreatmentcostofskeletalrelatedeventsinpatientswithmetastaticbreastorprostatecancerestimationfortheportuguesenationalhealthsystem
‡A
Hospital Resource Utilization and Treatment Cost of Skeletal-Related Events in Patients with Metastatic Breast or Prostate Cancer: Estimation for the Portuguese National Health System
‡9
1
|
|
919
|
|
|
‡a
healthopportunitycostsassessingtheimplicationsofuncertaintyusingelicitationmethodswithexperts
‡A
Health Opportunity Costs: Assessing the Implications of Uncertainty Using Elicitation Methods with Experts
‡9
1
|
|
919
|
|
|
‡a
economicevaluationofhealthcaretechnologiesusingprimaryresearch
‡A
Economic evaluation of healthcare technologies using primary research
‡9
1
|
|
919
|
|
|
‡a
criticalappraisalofcosteffectivenessandcostutilitystudiesinhealthcare
‡A
Critical appraisal of cost-effectiveness and cost-utility studies in health care
‡9
1
|
|
919
|
|
|
‡a
costeffectivenessanalysisoflarvaltherapyforlegulcers
‡A
Cost effectiveness analysis of larval therapy for leg ulcers.
‡9
1
|
|
919
|
|
|
‡a
clinicalandcosteffectivenessofcompressionhosieryversuscompressionbandagesintreatmentofvenouslegulcersvenouslegulcerstudy4venus4arandomisedcontrolledtrial
‡A
Clinical and cost-effectiveness of compression hosiery versus compression bandages in treatment of venous leg ulcers (Venous leg Ulcer Study IV, VenUS IV): a randomised controlled trial
‡9
1
|
|
919
|
|
|
‡a
capecitabineforthetreatmentofadvancedgastriccancer
‡A
Capecitabine for the treatment of advanced gastric cancer.
‡9
1
|
|
919
|
|
|
‡a
bevacizumabincombinationwithataxaneforthe1linetreatmentofher2negativemetastaticbreastcancer
‡A
Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer
‡9
1
|
|
919
|
|
|
‡a
evaluationofthefeasibilitycostandvalueofinformationofamulticentrerandomisedcontrolledtrialofintravenousimmunoglobulinforsepsisseveresepsisandsepticshockincorporatingasystematicreviewmetaanalysisandvalueofinf
‡A
An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of inf
‡9
1
|
|
919
|
|
|
‡a
evaluationofthefeasibilitycostandvalueofinformationofamulticentrerandomisedcontrolledtrialofintravenousimmunoglobulinforsepsisseveresepsisandsepticshockincorporatingasystematicreviewmetaanalysisandvalue
‡A
An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value [...]
‡9
1
|
|
919
|
|
|
‡a
adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiathearrestrct
‡A
Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT
‡9
1
|
|
919
|
|
|
‡a
adjunctiverifampicintoreduceearlymortalityfromstaphylococcusaureusbacteraemiaarreststudyprotocolforarandomisedcontrolledtrial
‡A
Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia (ARREST): study protocol for a randomised controlled trial
‡9
1
|
|
919
|
|
|
‡a
accountingforheterogeneityinrelativetreatmenteffectsforuseincosteffectivenessmodelsandvalueofinformationanalyses
‡A
Accounting for Heterogeneity in Relative Treatment Effects for Use in Cost-Effectiveness Models and Value-of-Information Analyses.
‡9
1
|
|
919
|
|
|
‡a
pragmaticmulticenteredrandomizedcontrolledtrialofyogaforchroniclowbackpaineconomicevaluation
‡A
A pragmatic multicentered randomized controlled trial of yoga for chronic low back pain: economic evaluation
‡9
1
|
|
919
|
|
|
‡a
pragmaticmulticentredrandomisedcontrolledtrialofyogaforchroniclowbackpaintrialprotocol
‡A
A pragmatic multi-centred randomised controlled trial of yoga for chronic low back pain: trial protocol
‡9
1
|
|
919
|
|
|
‡a
pilotrandomisedcontrolledtrialofnegativepressurewoundtherapytotreatgrade34pressureulcers
‡A
A pilot randomised controlled trial of negative pressure wound therapy to treat grade III/IV pressure ulcers [ISRCTN69032034].
‡9
1
|
|
919
|
|
|
‡a
intravenousimmunoglobulinforseveresepsisandsepticshockclinicaleffectivenesscosteffectivenessandvalueofafurtherrandomisedcontrolledtrial
‡A
Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial
‡9
1
|
|
919
|
|
|
‡a
venus4venouslegulcerstudy4compressionhosierycomparedwithcompressionbandaginginthetreatmentofvenouslegulcersarandomisedcontrolledtrialmixedtreatmentcomparisonanddecisionanalyticmodel
‡A
VenUS IV (Venous leg Ulcer Study IV) - compression hosiery compared with compression bandaging in the treatment of venous leg ulcers: a randomised controlled trial, mixed-treatment comparison and decision-analytic model
‡9
1
|
|
919
|
|
|
‡a
venus2arandomisedcontrolledtrialoflarvaltherapyinthemanagementoflegulcers
‡A
VenUS II: a randomised controlled trial of larval therapy in the management of leg ulcers.
‡9
1
|
|
919
|
|
|
‡a
useofweeklylowdosehighfrequencyultrasoundforhardtohealvenouslegulcersthevenus3randomisedcontrolledtrial
‡A
Use of weekly, low dose, high frequency ultrasound for hard to heal venous leg ulcers: the VenUS III randomised controlled trial.
‡9
1
|
|
919
|
|
|
‡a
clinicaleffectivenessandcosteffectivenessoftechnologiesusedtovisualisetheseizurefocusinpeoplewithrefractoryepilepsybeingconsideredforsurgeryasystematicreviewanddecisionanalyticalmodel
‡A
The clinical effectiveness and cost-effectiveness of technologies used to visualise the seizure focus in people with refractory epilepsy being considered for surgery: a systematic review and decision-analytical model.
‡9
1
|
|
919
|
|
|
‡a
addedclinicalandeconomicvalueofdiagnostictestingforepilepsysurgery
‡A
The added clinical and economic value of diagnostic testing for epilepsy surgery.
‡9
1
|
|
919
|
|
|
‡a
systematicreviewandmixedtreatmentcomparisondressingstohealdiabeticfootulcers
‡A
Systematic review and mixed treatment comparison: dressings to heal diabetic foot ulcers.
‡9
1
|
|
919
|
|
|
‡a
pointofcarecreatinineteststoassesskidneyfunctionforoutpatientsrequiringcontrastenhancedctimagingsystematicreviewsandeconomicevaluation
‡A
Point-of-care creatinine tests to assess kidney function for outpatients requiring contrast-enhanced CT imaging: systematic reviews and economic evaluation
‡9
1
|
|
919
|
|
|
‡a
networkmetaanalysisofindividualpatienttimetoeventdataalongsideaggregatecountdata
‡A
Network meta-analysis of (individual patient) time to event data alongside (aggregate) count data
‡9
1
|
|
919
|
|
|
‡a
modelosdedecisaoparaavaliacoeseconomicasdetecnologiasemsaude
‡A
Modelos de decisão para avaliações econômicas de tecnologias em saúde
‡9
1
|
|
919
|
|
|
‡a
methodstoelicitexpertsbeliefsoveruncertainquantitiesapplicationtoacosteffectivenesstransitionmodelofnegativepressurewoundtherapyforseverepressureulceration
‡A
Methods to elicit experts' beliefs over uncertain quantities: application to a cost effectiveness transition model of negative pressure wound therapy for severe pressure ulceration
‡9
1
|
|
919
|
|
|
‡a
methodstoassesscosteffectivenessandvalueoffurtherresearchwhendataaresparsenegativepressurewoundtherapyforseverepressureulcers
‡A
Methods to assess cost-effectiveness and value of further research when data are sparse: negative-pressure wound therapy for severe pressure ulcers
‡9
1
|
|
919
|
|
|
‡a
methodsfortheestimationofthenationalinstituteforhealthandcareexcellencecosteffectivenessthreshold
‡A
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold
‡9
1
|
|
919
|
|
|
‡a
makingbestuseofevidenceforexplicitdecisionsinhealthcare
‡A
Making best use of evidence for explicit decisions in health care
‡9
1
|
|
919
|
|
|
‡a
larvaltherapyforlegulcersvenus2randomisedcontrolledtrial
‡A
Larval therapy for leg ulcers (VenUS II): randomised controlled trial.
‡9
1
|
|
919
|
|
|
‡a
larvaltherapyforlegulcers
‡A
Larval therapy for leg ulcers
‡9
1
|
|
946
|
|
|
‡a
a
‡9
1
|
|
996
|
|
|
‡2
BLBNB|001134433
|
|
996
|
|
|
‡2
LC|no2014001906
|
|
996
|
|
|
‡2
PTBNP|1691048
|
|
996
|
|
|
‡2
ISNI|0000000080462563
|
|
996
|
|
|
‡2
SUDOC|204584191
|
|
996
|
|
|
‡2
BLBNB|000584169
|
|
996
|
|
|
‡2
NUKAT|n 2022171083
|
|
996
|
|
|
‡2
DNB|1044502746
|
|
996
|
|
|
‡2
PTBNP|1641696
|
|
996
|
|
|
‡2
DNB|1201751748
|
|
996
|
|
|
‡2
J9U|987010679693205171
|
|
996
|
|
|
‡2
LC|no2014027788
|
|
996
|
|
|
‡2
ISNI|0000000384407723
|
|
996
|
|
|
‡2
ISNI|0000000069999490
|
|
996
|
|
|
‡2
LC|n 2011037172
|
|
996
|
|
|
‡2
DNB|1043649719
|
|
996
|
|
|
‡2
ISNI|0000000373456335
|
|
996
|
|
|
‡2
DNB|1057331899
|
|
996
|
|
|
‡2
PTBNP|1584289
|
|
996
|
|
|
‡2
ISNI|0000000120850879
|
|
996
|
|
|
‡2
BLBNB|000538495
|
|
996
|
|
|
‡2
LC|nr2005019005
|
|
996
|
|
|
‡2
PTBNP|193217
|
|
996
|
|
|
‡2
PTBNP|199249
|
|
996
|
|
|
‡2
PTBNP|1536093
|
|
996
|
|
|
‡2
PTBNP|1884332
|
|
996
|
|
|
‡2
LC|n 2012211027
|
|
996
|
|
|
‡2
PTBNP|1294876
|
|
996
|
|
|
‡2
ISNI|000000007030844X
|
|
996
|
|
|
‡2
ISNI|0000000426676770
|
|
996
|
|
|
‡2
PTBNP|1211499
|
|
996
|
|
|
‡2
BLBNB|000200804
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
|
998
|
|
|
‡a
Soares, Marta O.
‡2
LC|n 2010182193
‡3
suggested
‡3
title: (0.99, 'evaluationofthefeasibilitycostandvalueofinformationofamulticentrerandomisedcontrolledtrialofintravenousimmunoglobulinforsepsisseveresepsisandsepticshockincorporatingasystematicreviewmetaanalysisandvalueofinformationanalysis', 'evaluationofthefeasibilitycostandvalueofinformationofamulticentrerandomisedcontrolledtrialofintravenousimmunoglobulinforsepsisseveresepsisandsepticshockincorporatingasystematicreviewmetaanalysisandvalueofinf')
|
